Osteosarcoma-Derived Extracellular Vesicles Induce Lung Fibroblast Reprogramming.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
30 Jul 2020
Historique:
received: 09 07 2020
revised: 23 07 2020
accepted: 29 07 2020
entrez: 6 8 2020
pubmed: 6 8 2020
medline: 17 2 2021
Statut: epublish

Résumé

Tumor-secreted extracellular vesicles (EVs) have been identified as mediators of cancer-host intercellular communication and shown to support pre-metastatic niche formation by modulating stromal cells at future metastatic sites. While osteosarcoma, the most common primary malignant bone tumor in children and adolescents, has a high propensity for pulmonary metastases, the interaction of osteosarcoma cells with resident lung cells remains poorly understood. Here, we deliver foundational in vitro evidence that osteosarcoma cell-derived EVs drive myofibroblast/cancer-associated fibroblast differentiation. Human lung fibroblasts displayed increased invasive competence, in addition to increased α-smooth muscle actin expression and fibronectin production upon EV treatment. Furthermore, we demonstrate, through the use of transforming growth factor beta receptor 1 (TGFBR1) inhibitors and CRISPR-Cas9-mediated knockouts, that TGFβ1 present in osteosarcoma cell-derived EVs is responsible for lung fibroblast differentiation. Overall, our study highlights osteosarcoma-derived EVs as novel regulators of lung fibroblast activation and provides mechanistic insight into how osteosarcoma cells can modulate distant cells to potentially support metastatic progression.

Identifiants

pubmed: 32751693
pii: ijms21155451
doi: 10.3390/ijms21155451
pmc: PMC7432951
pii:
doi:

Substances chimiques

ACTA2 protein, human 0
Actins 0
Receptor, Transforming Growth Factor-beta Type I EC 2.7.11.30

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

J Natl Cancer Inst. 2014 Feb;106(2):djt369
pubmed: 24511106
J Biol Chem. 2007 May 18;282(20):14984-91
pubmed: 17371880
Cancer Res. 2010 Dec 1;70(23):9621-30
pubmed: 21098712
Cancer Cell. 2016 Aug 8;30(2):243-256
pubmed: 27505671
Mol Cancer Res. 2018 Jul;16(7):1196-1204
pubmed: 29636362
Cancer Res. 2002 Oct 1;62(19):5543-50
pubmed: 12359766
Oncoimmunology. 2020 Apr 12;9(1):1747677
pubmed: 32313728
J Bone Miner Res. 2013 Apr;28(4):838-47
pubmed: 23169460
Cancers (Basel). 2019 Jun 05;11(6):
pubmed: 31195680
Nat Rev Immunol. 2002 Aug;2(8):569-79
pubmed: 12154376
Oncotarget. 2016 Jul 12;7(28):43570-43587
pubmed: 27259278
Orphanet J Rare Dis. 2007 Jan 23;2:6
pubmed: 17244349
J Extracell Vesicles. 2019 Apr 14;8(1):1599680
pubmed: 31044053
Oncogene. 2019 Jul;38(28):5566-5579
pubmed: 31147602
Bioinformatics. 2015 Apr 1;31(7):1120-3
pubmed: 25414360
Nat Commun. 2017 May 05;8:15178
pubmed: 28474669
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Nat Rev Cancer. 2014 Nov;14(11):722-35
pubmed: 25319867
J Exp Clin Cancer Res. 2016 Jul 16;35(1):113
pubmed: 27421768
Nature. 2017 Jun 22;546(7659):498-503
pubmed: 28607485
Curr Protoc Cell Biol. 2006 Apr;Chapter 3:Unit 3.22
pubmed: 18228490
Cells. 2020 Jan 17;9(1):
pubmed: 31963599
Nature. 2015 Nov 19;527(7578):329-35
pubmed: 26524530
Cancer Cell. 2016 Nov 14;30(5):668-681
pubmed: 27846389
J Pathol. 1998 Jul;185(3):284-9
pubmed: 9771482
Carcinogenesis. 2020 Jul 10;41(5):666-677
pubmed: 31294446
Nature. 2005 Dec 8;438(7069):820-7
pubmed: 16341007
Oncotarget. 2015 Jun 10;6(16):14413-27
pubmed: 26015407
Oncogene. 2015 Jan 15;34(3):290-302
pubmed: 24441045
Cancer Treat Rev. 2014 May;40(4):523-32
pubmed: 24345772
Biochem Biophys Res Commun. 2018 Jun 2;500(2):170-176
pubmed: 29626470
J Exp Clin Cancer Res. 2018 Oct 3;37(1):242
pubmed: 30285793
J Clin Med. 2016 Nov 03;5(11):
pubmed: 27827889
Cancer Cell. 2019 Jan 14;35(1):33-45.e6
pubmed: 30645975
Int J Cell Biol. 2012;2012:676731
pubmed: 22505933
Nat Methods. 2014 Aug;11(8):783-784
pubmed: 25075903
Cancer Cell. 2016 Dec 12;30(6):836-848
pubmed: 27960084
Sci Rep. 2015 Oct 21;5:15338
pubmed: 26486848
Nat Cell Biol. 2019 Jan;21(1):9-17
pubmed: 30602770
Dev Cell. 2019 May 6;49(3):347-360
pubmed: 31063754
Nat Med. 2012 Jun;18(6):883-91
pubmed: 22635005
Nat Commun. 2015 May 13;6:7164
pubmed: 25968605
Front Bioeng Biotechnol. 2016 Feb 12;4:12
pubmed: 26904541
Transl Oncol. 2014 Jun 17;7(3):331-40
pubmed: 25180057
Transl Oncol. 2017 Jun;10(3):419-430
pubmed: 28448958
Nat Rev Cancer. 2017 May;17(5):302-317
pubmed: 28303905
Clin Cancer Res. 2017 Jul 15;23(14):3721-3733
pubmed: 28053020
Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3725-30
pubmed: 21321210
PLoS One. 2013 Sep 10;8(9):e74045
pubmed: 24040160
Clin Cancer Res. 2014 Oct 1;20(19):5097-112
pubmed: 25107916
Nat Cell Biol. 2015 Jun;17(6):816-26
pubmed: 25985394

Auteurs

Alekhya Mazumdar (A)

Department of Orthopedics, Balgrist University Hospital, CH-8008 Zurich, Switzerland.
Institute for Biomechanics, ETH Zurich, CH-8008 Zurich, Switzerland.

Joaquin Urdinez (J)

Department of Orthopedics, Balgrist University Hospital, CH-8008 Zurich, Switzerland.
Institute for Biomechanics, ETH Zurich, CH-8008 Zurich, Switzerland.

Aleksandar Boro (A)

Department of Orthopedics, Balgrist University Hospital, CH-8008 Zurich, Switzerland.

Jessica Migliavacca (J)

Department of Oncology, Children's Research Center, University Children's Hospital Zürich, CH-8032 Zurich, Switzerland.

Matthias J E Arlt (MJE)

Department of Orthopedics, Balgrist University Hospital, CH-8008 Zurich, Switzerland.
Institute for Biomechanics, ETH Zurich, CH-8008 Zurich, Switzerland.

Roman Muff (R)

Department of Orthopedics, Balgrist University Hospital, CH-8008 Zurich, Switzerland.

Bruno Fuchs (B)

Department of Orthopedics, Balgrist University Hospital, CH-8008 Zurich, Switzerland.

Jess Gerrit Snedeker (JG)

Department of Orthopedics, Balgrist University Hospital, CH-8008 Zurich, Switzerland.
Institute for Biomechanics, ETH Zurich, CH-8008 Zurich, Switzerland.

Ana Gvozdenovic (A)

Department of Orthopedics, Balgrist University Hospital, CH-8008 Zurich, Switzerland.
Institute for Biomechanics, ETH Zurich, CH-8008 Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH